Drivers of temporal improvement in CAR T-cell therapy for large B-cell lymphoma: a Japanese nationwide registry analysis.

In an exploratory comparison, PFS did not differ significantly between patients receiving polatuzumab vedotin– and platinum-based bridging chemotherapy, although a numerical trend toward improved outcomes was observed in the polatuzumab vedotin–based group across the different products (tisa-cel [HR, 0.82; P = .34]; liso-cel [HR, 0.72; P = .34]; supplemental Figure 2 ).

also in 1,012 other papers